Background. Almost 30% of chronic haemodialysis (HD) patients are dependent on central venous catheters (CVCs) for their vascular access, and catheter-related bacteraemia (CRB) is the major reason for catheter loss and has been associated with substantial morbidity, including meta-static infections. This systematic review evaluates the benefits and harms of antimicrobial interventions for the prevention of catheter-related infections (CRIs). Methods. MEDLINE (1950-May 2009), EMBASE (1980-May 2009) CENTRAL (up to May 2009) and bibliographies of retrieved articles were searched for relevant RCTs. Analysis was by a random effects model and results expressed as rate ratio, relative risk (RR) and weighted mean difference (WMD) with 95% confidence intervals (CI). Results. A total of 29 trials with 2886 patients and 3005 catheters were included. Antimicrobial catheter locks (AMLs) significantly reduced the rates of CRBs (rate ratio, 0.33, 95% CI 0.24-0.45) and exit-site infections (ESIs) (rate ratio 0.67, 95% CI 0.47-0.96). Exit-site antimicrobial application also significantly reduced the rates of CRBs (rate ratio 0.21, 95% CI 0.12-0.36) and ESIs (rate ratio 0.22, 95% CI 0.10-0.47). Antimicrobial coating of HD catheters and the use of peri-operative antimicrobials did not result in significant reduction in rates of CRBs and ESIs. Conclusion. The use of AMLs and exit-site antimicrobials are useful measures in the reduction of CRIs, whereas antimicrobial impregnated catheters and peri-operative systemic antimicrobial administration have not been found to be beneficial. Further head-to-head trials of various AMLs and exit-site antimicrobials are needed to know about their comparative clinical efficacy.
Introduction
Central venous catheters (CVCs) continue to be used in a significant proportion of chronic haemodialysis (HD) patients for vascular access despite recommendations by several national and international guidelines to minimize their usage as much as possible. It has been estimated that almost 30% of chronic HD patients are dependent on CVCs for their vascular access [1, 2] . CVCs are responsible for almost half of all infections in HD patients even though they represent the smallest fraction of accesses [3] . CVCs have significantly higher rates of infections when compared with grafts and fistulae. It has been estimated that the relative risk (RR) for infection in tunnelled cuffed catheters (TCC) and uncuffed catheters (UCs) when compared with native arteriovenous fistulae (AVF) is 15.5 and 25.5, respectively [4] . The infection rate in TCCs have been reported to range from 1.6 to 5.5 episodes per 1000 catheterdays and in UCs from 3.8 to 6.6 episodes per 1000 catheter days [5, 6] . The most important risk factors for catheterrelated infections (CRIs) include the presence of diabetes, peripheral atherosclerosis, a previous history of bacteraemia, nasal carriage of Staphylococcus aureus, longer duration of catheter use and local infection [7, 8] . Infection is the leading cause of catheter removal and morbidity in dialysis patients [9, 10] . Catheter-related bacteraemia (CRB) is the major reason for catheter loss and has been associated with substantial morbidity, including meta-static infection [11, 12] . The costs to the health care system are also substantial. It has been estimated from the United States Renal Data System and Medicare reimbursement data that there are approximately 100 000 episodes of CRB per year in the US and at an average cost of $22 000 per episode of CRB, the total cost of these infections may well approach dollar 1 billion [13, 14] .
Several techniques have been used to decrease the incidence of CRB. These include the use of systemic (usually by intravenous route) antibiotics around the time of catheter implantation, antimicrobial locks (AMLs) instilled into the catheter lumen, antimicrobial impregnated catheters, exitsite antimicrobials (ESAs) and agents used to reduce nasal colonization [15] [16] [17] [18] [19] . The main health risks associated with antimicrobial interventions include side effects such as ototoxicity with gentamicin, and hypocalcaemia and metallic taste with citrate, and the possible emergence of resistant organisms [20, 21] . These interventions also entail additional costs to the health care provider. Currently, none of the renal societies have guidelines regarding the use of antimicrobial interventions to prevent CRI.
Methods
Guidelines from the Cochrane Renal Group and the QUOROM statement for undertaking and reporting systematic reviews were followed [22] .
Inclusion criteria
We included any randomized controlled trial (RCT) of antimicrobial agents used to prevent CRIs in HD patients, regardless of whether the antimicrobials were tested between themselves (head-to-head) or against placebo/control intervention such as heparin. Trials of the following agents were included: peri-operative systemic antimicrobials (defined as antimicrobials given just a few hours before or after insertion of the HD catheter), AMLs, exit-site antimicrobial application (ESAs), treatment of nasal S. aureus carriage before or after catheter insertion, antimicrobial coating of catheters or catheter components such as catheter cuffs. The trials exclusively assessing the effectiveness of catheter type and insertion technique were excluded.
Search strategy
Electronic searches were performed using MEDLINE (1966 by using optimally sensitive search strategies for identification of RCTs developed by the Cochrane Collaboration. The following medical subject heading terms and text words were used: HD, catheters and antibacterial agents. Additionally, relevant text words relating to all investigated interventions were used. Based on standard systematic review methods, titles and abstracts identified by these searches were screened initially by two of the authors (K.S.R and R.D). No language restrictions were applied. Studies that clearly did not meet inclusion criteria (i.e. animal studies, non-RCTs and RCTs of interventions that were not stated a priori in inclusion criteria for this review) were not considered further. The full text (if published or otherwise available) of all other studies was assessed by two independent reviewers (K.S.R. and R.D.) for eligibility criteria. Disputes were solved in consultation with a third investigator (C.M.).
Data extraction
From all included RCTs, data were extracted by at least two of four authors (K.S.R., T.B., J.A., R.S.) independently on the following outcomes when they were reported: CRB (no. of patients with CRB, CRB episodes per 1000 catheter-days), exit-site infections (ESI) (no. of patients with ESI, ESI episodes per 1000 catheter-days), catheter thrombosis (no. of patients with catheter thrombosis), loss of catheter due to any complication, hospitalization (no. of patients hospitalized, no. of hospitalization days), all-cause mortality and mortality due to CRIs. 
Excluded (n=47)
Nonrandomized studies (n=19) Patient population not relevant to review (n=7)
Interventions not relevant to review (n=4) Editorials/Review articles (n= 12) Economic evaluation (n=1) Systematic reviews/Meta-analysis (n=4) 
Quality assessment
The quality of included randomized trials was assessed using standard criteria (allocation concealment, intention-to-treat analysis, loss to followup and blinding). Any differences in data extraction were resolved by discussion among authors. When data were missing or incomplete, investigators of the trials were contacted by written correspondence for clarification.
Statistical analysis
Treatment effects were summarized with the RR measure and its 95% confidence intervals (CIs) for dichotomous outcomes and weighted mean difference (WMD) and its 95% CIs for continuous outcomes. Estimates from individual RCTs were pooled using the DerSimonian and Laird random-effects model, when appropriate. The Mantel-Haenszel fixedeffect model was also computed to evaluate robustness and susceptibility to outliers. Where data on the number of episodes were available, the rate ratio was calculated as the ratio of the rate of the outcome (e.g. the CRB rate) in the experimental treatment group (given by number of episodes of the outcome over unit time) over the rate in the control group. The generic inverse variance method was used to calculate rate ratios and their 95% CIs. The rate ratio shows the reduction in the incidence rate in the experimental intervention group compared to that in the control intervention group. For example, a rate ratio of 0.6 indicates a 40% reduction in events in the experimental intervention group compared to those on the control intervention. Heterogeneity of treatment effects between studies was formally tested using the Q (heterogeneity chi-square) and I 2 statistics. Subgroup analysis was planned to explore how possible sources of heterogeneity (type of catheter, catheter vintage) might have influenced treatment effect when these data were reported in the trials or provided by the investigators on request. All analyses were undertaken using RevMan 4.2.10 (2006; The Cochrane Collaboration, Oxford, UK).
Results

Literature search
The combined search identified 3343 articles, of which 3265 articles were excluded initially (see Figure 1 ). Major reasons for exclusion were (1) duplicate references, (2) non-RCTs, (3) RCTs of other interventions not stated in the inclusion criteria and (4) animal and basic research studies. Full-text assessment of 78 potentially eligible reports identified 29 eligible RCTs [15] [16] [17] [18] [19] [20] [21] , with 2886 patients and 3005 catheters published in 31 reports.
Trial characteristics
The trial characteristics are summarized in Table 1 . A total of 19 trials evaluated the efficacy of AMLs [17, 21, [23] [24] [25] [26] [28] [29] [30] 32, [35] [36] [37] [38] [40] [41] [42] [43] [44] . ESAs were evaluated in six trials [15, 18, 31, 33, 34, 39] . There were three trials of antimicrobial coating of catheter or catheter components such as catheter cuff [19, 27, 29] and one of peri-operative systemic antibiotics [16] . Two studies were published only in a conference abstract format [23, 28] .
There were four trials that had head-to-head comparison of antimicrobial interventions [15, 17, 36, 39] . In the trial by Nori et al., patients were divided into three groups [17] . One group was allocated to receive gentamicin lock, the other to minocycline-EDTA lock and the third to heparin lock. The trial by Johnson et al. compared exit-site application [21, 24, 25] . The catheter vintage was unclear in two study reports [28, 43] , included both old and new catheters in one study [17] , old catheters alone in two studies [38, 44] and all the other studies (24 of 29) only assessed newly inserted HD catheters [15, 16, [18] [19] [20] [21] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [39] [40] [41] [42] .
Skin cleaning with povidone-iodine or chlorhexidine solutions or the application of povidone-iodine ointment after each dialysis session appeared to be the most common cointerventions. Only one trial [36] was a crossover study, and all the rest had a parallel study design. [23, 26, [28] [29] [30] 42] . Eight trials had blinding of patient, heath care provider and outcome assessors [20, 21, 25, 27, 34, [40] [41] [42] . The patients and health care providers alone were blinded in two trials [32, 36] , and one trial had blinding of patients alone [18] . The results were analysed on an intention-to-treat basis in 26 trials [15] [16] [17] [19] [20] [21] 23, 24, 26, [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] . A total of 20 patients out of 2886 (0.69%) were lost to follow-up.
Trial quality
Effectiveness of interventions
The details of the total number of catheter days and the number of CRB episodes per 1000 catheter-days are given in Table 2 .
AMLs. AMLs were found to have significantly reduced rates of CRB (15 trials, rate ratio, 0.33, 95% CI 0.24-0.45) and ESI (10 trials, rate ratio 0.67, 95% CI 0.47-0.96) (see Figure 2) . Similarly, AMLs significantly reduced the risk of CRB (12 trials, 1047 patients, RR 0.22, 95% 0.13 to 0.35) and ESI (five trials, 498 patients, RR 0.33, 95% CI 0.19-0.58) and catheter loss due to all complications (three trials, 399 patients, RR 0.61, 95% CI 0.45-0.83). There was no significant heterogeneity between the studies for the outcomes mentioned above.
Exit-site antimicrobial application. ESAs significantly reduced rates of CRB (four trials, rate ratio 0.21, 95% CI 0.12-0.36) and ESI (three trials, rate ratio 0.22, 95% CI 0.10-0.47) (see Figure 3) . Similarly, ESAs significantly reduced the risk of CRB (four trials, 477 patients, RR 0.35, 95% CI 0.23-0.52), ESI (two trials, 179 patients, RR 0.22, 95% CI 0.07-0.66) and catheter loss due to all complications (two trials, 298 patients, RR 0.54, 95% CI 0.29-0.99). There was no significant heterogeneity between the studies for the outcomes mentioned above. 
Peri-operative systemic antimicrobial administration.
Peri-operative antimicrobial administration (intravenous vancomycin 1-2 h post-insertion of catheter) was not found to significantly reduce rates of CRB (one trial, rate ratio 0.66, 95% CI 0.27-1.63) or ESI (one trial, rate ratio 0.87, 95% CI 0.45-1.65). Similarly, peri-operative antimicrobials also did not result in a significant reduction in risk with respect to CRB (one trial, 110 patients, RR 0.78, 95% CI 0.34-1.76) or ESI (one trial, 110 patients, RR 1.02, 95% CI 0.60-1.72). It must be noted that this study was performed in patients with non-tunnelled HD catheters alone.
Head-to-head comparison of antimicrobials.
The patients on mupirocin and Medihoney were found to have similar risk of CRB (one trial, 101 patients, RR 1.18, 95% CI 0.38-3.61) and ESI (effect measures not estimable as this outcome did not occur during the trial period). Honey when compared to mupirocin or povidone-iodine did not significantly reduce the rates of CRB (two trials, rate ratio 0.86, 95% CI 0.35-2.12) and ESI (two trials, rate ratio 0.81, 95% CI 0.16-4.12). In the study by Nori et al. comparing gentamicin and micocycline-EDTA AMLs, no difference was found between patients in either group for the risk of CRB (one trial, 41 patients, RR 0.35, 95% CI 0.02-8.10) [17] . One study [34] compared 5% citrate and 10% citrate AMLs. The results were not in a meta-analysable format, but this study did not report any difference between either intervention for the risk of CRIs or thrombosis.
Complications relating to antimicrobial agent used. Four patients were found to have dizziness in the gentamicin/citrate group in the study by Dogra et al. [20] . In another study, nine patients in the tri-sodium citrate group and four in the heparin group had perioral or peripheral paraesthesia or metallic taste [21] . Symptoms disappeared within 1 min of lock instillation and did not return.
Emergence of resistant organisms. One patient had reported MRSA infection in studies by Chatzinoklaou et al. and McIntyre et al. [26, 33] . In the study by Dogra et al., one candida ESI was reported [20] .
Other outcomes. The data regarding other outcomes such as catheter thrombosis and mortalities (all-cause and CRB related) when reported have been presented in Table 3 .
Subgroup analysis. Sufficient numbers of studies were available only for effect of AMLs on CRB rates according to the type of catheter (tunnelled or non-tunnelled). From the studies that used both types of catheters [21, 24, 25] , separate data for both types of catheter were available only from the Weijmer et al. study to be used in this analysis [21] . AMLs significantly reduced CRB rates both for tunnelled (rate ratio 0.28, 95% CI 0.18-0.43) and non-tunnelled catheters (rate ratio 0.50, 95% CI 0.36-0.68).
Discussion
This systematic review of antimicrobial interventions for the prevention of HD CRIs shows a number of key findings. The use of AMLs and ESAs significantly reduces the risk and rate of CRB and ESI, and the risk of catheter loss due [17] . Similarly, exit-site application of honey compared to other antimicrobials (mupirocin and povidoneiodine) was found to be of similar efficacy in the prevention of CRI. The rate of CRB in the control arms of the included studies varied greatly ranging from 0.47 to 15.46 per 1000 catheter-days. The presence of a dialysis catheter has been shown to be a major risk factor for bacteraemia and can result in life-threatening complications, including septic shock, endocarditis, septic arthritis, osteomyelitis or epidural abscess [45] . One study has calculated that there are 2750-5500 deaths due to CRB in the HD population in the USA assuming that the mortality rate due to CRB is 5-10% and that there are two CRB events per 1000 patient-days for patients with tunnelled catheters [46] . Thus, CRB in the HD population can have an enormous adverse impact on patient outcomes and can translate into increased consumption of health care resources.
The efficacy of AMLs in the prevention of CRB is striking. The use of AMLs has been shown in our analysis to result in the reduction of risk of CRB by 75%. With regard to effect of AMLs on ESI, the meta-analysis shows that only the study by Weijmer et al. [21] showed a significant reduction in both the rate and risk for this outcome, whilst the others did not. However, due to the size of this study, it influenced the summary outcome as well showing a difference in favour of AMLs in terms of ESI prevention. None of the studies showed the emergence of resistant organisms; however, the studies were not designed to answer this question. Although the use of AMLs has demonstrated effectiveness at reducing the incidence of CRB, there continues to be a hesitance to their overall use, likely due to the concern for the potential for development of drug resistance. It has been known from previous studies that the use of antimicrobials can cause the emergence of drug-resistant organisms [47] . The studies included in this review were of relatively short duration, with most of them lasting <1 year, and the patient numbers were relatively small. It is therefore not possible to state that the use of AMLs in the long term will be risk-free from a drug resistance point of view. Almost 10% of the patients in the Dogra et al. study experienced ototoxicity; however, the authors used a higher concentration of gentamicin (40 mg/ml) [20] . This systemic exposure was not seen in the McIntyre et al. study, which used a concentration of 5 mg/ml [33] . It must be noted that none of the studies performed formal audiometry to assess ototoxicity. Citrate locks possibly provide a fairly wider therapeutic window than other AMLs in that the major side effect reported was metallic taste. No major trials have been reported so far in the literature showing evidence of emergence of drug resistant organisms with this agent.
None of the current guidelines relating to the use of intravascular devices provide consistent guidelines with regard to the use of antimicrobial interventions apart from the use of chlorhexidine skin cleansing (Table 4) .
Several meta-analysis and reviews have been published on the use of antimicrobials for the prevention of infections relating to the use of CVCs. A meta-analysis published in 2002 assessed studies that compared the risk for CRB in patients with CVCs following insertion-site skin care with either any type of chlorhexidine gluconate solution versus povidone-iodine (PI) solution [53] . This analysis indicated that the use of chlorhexidine solution rather than povidoneiodine can reduce the risk for CRB by ∼49% (RR 0.51, CI 0.27-0.97) in hospitalized patients who require shortterm catheterization. One meta-analysis reported that the use of CVCs impregnated with chlorhexidine and silver sulfadiazine significantly reduced the odds of CRB (Odds ratio 0.44, 95% CI 0.36-0.54) [54] .
The main drawback with the meta-analyses reported above is that none of them included trials in the HD population. It may well be that interventions that are useful with central vascular access devices in other settings (total parenteral nutrition, central lines for chemotherapy administration, etc.) may not be effective in the HD population as the nature of the dialysis catheter, i.e. its chemical composition, the frequency of their usage and the nature of their usage are Recommends the use of dry gauze instead of transparent dressings, disinfection with chlorhexidine solutions instead of povidone-iodine, the use of topical mupirocin or Medihoney or antiseptic at the catheter exit-site and the use of citrate and/or antibiotics with heparin as a catheter locking solution. European Renal Association (ERA-EDTA) [51] Recommends strict protocols for handling catheters based on aseptic manipulation and mentions that the regular and pre-emptive use of locking solutions (citrate) with both antithrombotic and/or antiseptic properties is effective in preventing catheter infection. The Evidence-Based Practice in Infection Control (EPIC) [52] Recommends the use of alcoholic chlorhexidine solution (2% chlorhexidine gluconate in 70% isopropyl alcohol) for skin cleansing prior to insertion of central venous catheters and also during handling of such catheters. The EPIC guidelines advocate against the use of AMLs and ESAs.
considerably different to other CVCs. Therefore, the results from the trials involving other types of CVCs should not automatically be considered applicable to HD catheters. Our literature search did not reveal any study that was a headto-head comparison of various skin cleansing antimicrobial solutions (chlorhexidine, povidone-iodine) for HD catheter care. Several renal units in the UK administer intravenous antibiotics, especially flucloxacillin or vancomycin prior to the insertion of tunnelled catheters (author's personal experience). The only trial that evaluated intravenous antibiotics in the peri-operative setting assessed its use in patients with non-tunnelled catheters alone. The use of peri-operative intravenous antibiotics for the prevention of CRI in patients with tunnelled catheters is therefore not currently supported by trial evidence.
S. aureus carriage has received attention in the literature as a possible source of infection in HD patients. A recently published trial looked at the carriage of MRSA and subsequent infection among dialysis patients, healthcare workers and their families within a single dialysis centre [55] . The investigators found that 36% of colonized subjects went on to develop MRSA infection with the same molecular phenotype as the colonizing strain. Two trials [56, 57] have reported a decrease in incidence of S. aureus-related infections with eradication of S. aureus carriage. However, neither of these trials included patients with HD catheters and therefore we currently do not have evidence regarding the effectiveness of eradicating S. aureus carriage on the reduction of HD CRI.
Whilst antimicrobials in the form of AMLs and exit-site applications have been impressively effective in the reductions of CRI, one should be mindful of addressing basic aspects effectively such as the use of masks and sterile gloves and the use of non-touch techniques. One study has shown that the adoption of a strict aseptic protocol alone significantly reduced the incidence of CRB [58] . The NKF-KDOQI guidelines recommend following the CDC guidelines with respect to aseptic handling of catheters, and the EPIC guidelines in the UK make similar recommendations [48, 49, 52] .
We feel that the judicious use of antimicrobials, especially in the form of AMLs and exit-site antibiotics, along with scrupulous attention to aseptic techniques during the handling of HD catheters, can lead to significant reductions in CRI and consequently reduce patient morbidity and mortality, and also reduce the financial burden incurred by the health care providers on account of such infections. However, we need to continue to be vigilant about emergence of a drug-resistant organism and continue to evaluate alternative antimicrobials agents (non-antibiotics) against which resistance is not possible (e.g. calcium chelators). Further, adequately powered and well-designed studies assessing the effectiveness of antimicrobial-coated catheters, peri-operative systemic antibiotic usage and head-to-head trial of various antimicrobials are recommended to inform us regarding their relative effectiveness.
